Acadia Pharmaceuticals (ACAD) PT Lowered to $24 at BMO Capital
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $28.38 -3.63%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $24.00 (from $31.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
- Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
- Cellebrite (CLBT) PT Lowered to $15 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
